| 날짜 |
제목 |
| 2024. 11. 19. |
Illumina announces expansion of TruSight Oncology portfolio |
| 2024. 11. 12. |
Comprehensive Genomic Profiling leads to better patient outcomes, new joint study says |
| 2024. 11. 6. |
Illumina To Webcast Upcoming Investor Conferences |
| 2024. 11. 4. |
Illumina Reports Financial Results for Third Quarter of Fiscal Year 2024 |
| 2024. 10. 31. |
Illumina to preview newest innovations in NGS and multiomic technologies at the American Society of Human Genetics Annual Meeting |
| 2024. 10. 9. |
Illumina introduces the MiSeq i100 Series: its simplest, fastest benchtop sequencers |
| 2024. 10. 7. |
Illumina to Announce Third Quarter 2024 Financial Results on Monday, November 4, 2024 |
| 2024. 10. 3. |
Charles Dadswell to step down as General Counsel, Illumina initiates search for successor |
| 2024. 9. 3. |
European Court of Justice rules in favor of Illumina in jurisdictional appeal |
| 2024. 8. 27. |
FDA approves Illumina cancer biomarker test with two companion diagnostics to rapidly match patients to targeted therapies |
| 2024. 8. 13. |
Illumina announces strategy to accelerate value creation |
| 2024. 8. 6. |
Illumina Reports Financial Results for Second Quarter of Fiscal Year 2024 |
| 2024. 8. 5. |
Illumina launches new oncology menu for NovaSeq X Series customers |
| 2024. 7. 18. |
Illumina to Present Upcoming Strategy Update |
| 2024. 7. 11. |
Illumina to Announce Second Quarter 2024 Financial Results on Tuesday, August 6, 2024 |
| 2024. 7. 9. |
Illumina acquires Fluent BioSciences to accelerate single-cell analysis and discovery to a broader customer base |
| 2024. 6. 24. |
Illumina completes the divestiture of GRAIL |
| 2024. 6. 11. |
Illumina DRAGEN v4.3 powers most comprehensive, accurate genome with industry-leading innovations |
| 2024. 6. 4. |
Illumina launches latest chemistry across most popular mid-throughput sequencers, enabling higher quality and greater speed for customers at lower cost |
| 2024. 6. 3. |
Illumina Board of Directors approves spin-off of GRAIL; declares spin-off dividend of GRAIL shares |
| 2024. 6. 3. |
Illumina appoints Everett Cunningham Chief Commercial Officer |
| 2024. 5. 29. |
Illumina drives genomic testing as standard of care in oncology through collaborative research presented at ASCO |
| 2024. 5. 28. |
Illumina releases 2023 Corporate Social Responsibility Report |
| 2024. 5. 20. |
Anna Richo joins Illumina's Board of Directors |
| 2024. 5. 15. |
Illumina To Webcast Upcoming Investor Conference |
| 2024. 5. 6. |
Illumina publicly files Form 10 registration statement ahead of planned divestiture of GRAIL |
| 2024. 5. 3. |
Illumina To Webcast Upcoming Investor Conference |
| 2024. 5. 2. |
Illumina Reports Financial Results for First Quarter of Fiscal Year 2024 |
| 2024. 4. 12. |
Illumina's planned divestment of GRAIL approved by the European Commission |
| 2024. 4. 9. |
Illumina appoints Ankur Dhingra Chief Financial Officer, Jakob Wedel Chief Strategy and Corporate Development Officer |
| 2024. 4. 4. |
Illumina to Announce First Quarter 2024 Financial Results on Thursday, May 2, 2024 |
| 2024. 2. 8. |
Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2023 |
| 2024. 1. 9. |
Illumina Announces Preliminary Financial Results for Fourth Quarter and Fiscal Year 2023 |
| 2024. 1. 5. |
Illumina expands collaboration with Janssen to advance molecular residual disease cancer test |
| 2024. 1. 4. |
Illumina to Announce Fourth Quarter and Full Year 2023 Financial Results on Thursday, February 8, 2024 |
| 2024. 1. 4. |
The Alliance for Genomic Discovery welcomes Bristol Myers Squibb, GSK, and Novo Nordisk |